Kathy L. Hibbs
Known title: DirectorCIK: 0001267487
Associated companies
Transaction History
| SOPH | ▼ Sell | Open Market | 6,250 | $51K | 9/8/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 6,250 | $54K | 8/25/2026 | View on chart |
| LAB | ▲ Buy | Grant | 99,116 | $0 | 6/18/2026 | View on chart |
| SOPH | ▲ Buy | Grant | 19,724 | $108K | 6/18/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 7,508 | $35K | 5/12/2026 | View on chart |
| LAB | ▲ Buy | Grant | 94,592 | $0 | 6/20/2025 | View on chart |
| LAB | ▲ Buy | Grant | 43,128 | $0 | 6/28/2024 | View on chart |
| LAB | ▲ Buy | Grant | 79,412 | $0 | 1/5/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum
Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum. Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.